Overview of Dr. Goldsmith
Dr. Scott Goldsmith is a hematologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from University of Florida College of Medicine and has been in practice 4 years. He specializes in hematologic oncology. He has more than 30 publications and over 450 citings.
Office
1500 Duarte Rd
Duarte, CA 91010Fax+1 314-362-6959- Is this information wrong?
Education & Training
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2013 - 2016
- University of Florida College of MedicineClass of 2013
Certifications & Licensure
- CA State Medical License 2021 - 2025
- MO State Medical License 2015 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Nov 22
- A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2021 Nov 11
Publications & Presentations
PubMed
- 10 citationsHematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?Scott R. Goldsmith, Armin Ghobadi, John F. DiPersio
Frontiers in Oncology. 2020-12-22 - 89 citationsPosttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott R. Goldsmith, Muhammad Bilal Abid, Jeffery J. Auletta, Asad Bashey, Amer Beitinjaneh
Blood. 2021-06-10 - 15 citationsNext Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass StudyScott R. Goldsmith, Mark A. Fiala, James Dukeman, Armin Ghobadi, Keith Stockerl-Goldstein
Clinical Lymphoma, Myeloma & Leukemia. 2019-05-01
Abstracts/Posters
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple MyelomaScott R. Goldsmith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: